# 2026-19849: FDA Asks for Input on Human Research Data Collection

2026-19849, Agency Information Collection Activities; Proposed Collection; Comment Request; Protection of Human Subjects and Institutional Review Boards, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-09-29, effective 2026-11-30; PRIA reads it as touching household money (as of 2026-10-06).

- Canonical: https://policyrisk.com/federal-register/2026-19849
- As of: 2026-10-06
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-19849
- Title: Agency Information Collection Activities; Proposed Collection; Comment Request; Protection of Human Subjects and Institutional Review Boards
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 61410
- Published: 2026-09-29
- Effective: 2026-11-30
- Comments close: 2026-11-30
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-06

## In one line

FDA Asks for Input on Human Research Data Collection

## Summary

The FDA wants your thoughts on how they collect info about medical devices to keep people safe. This affects anyone involved in medical research or device tracking and aims to improve how data is gathered without adding extra hassle. You’ve got until November 30, 2026, to share your comments, so don’t miss out on shaping the future of health safety!

## Abstract

The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection requirements for the tracking of medical devices.

## Effects PRIA read

- Written Informed Consent Required for FDA Studies: benefit, high. For clinical investigations regulated by FDA, investigators must obtain legally effective informed consent and document it using a written consent form that is IRB-approved and signed and dated by the subject or the subject's legally authorized representative. The basic elements required in consent…
- Large Time Burden on IRBs and Investigators: cost, high. The FDA estimates about 2,520 IRBs oversee FDA-regulated research and quantifies annual administrative burden: 1,363 hours for reporting tasks, 1,522,104 hours for recordkeeping tasks, and 103,336 hours for third-party disclosures. FDA assumes each IRB meets about 14.6 times per year and uses 40 pe…
- Certificates of Confidentiality Protect Research Privacy: benefit, medium. The 21st Century Cures Act requires issuance of Certificates of Confidentiality (CoCs) for federally-funded human subject research that collects or uses identifiable, sensitive information (mandatory CoCs), while CoCs remain discretionary for non-federally funded research. FDA issued guidance on Co…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-19849 on federalregister.gov](https://www.federalregister.gov/documents/2026/09/29/2026-19849/agency-information-collection-activities-proposed-collection-comment-request-protection-of-human)
- [2026-19849 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-09-29/pdf/2026-19849.pdf)

## Related
- [Previous: 2026-19848, Submission of Information Collection for OMB Review; Comment Request; Generic C…](https://policyrisk.com/federal-register/2026-19848)
- [Next: 2026-19850, Agency Information Collection Activities; Submission for Office of Management a…](https://policyrisk.com/federal-register/2026-19850)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-19849 (as of 2026-10-06).
